Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Non-Hodgkin Lymphoma

Kristie L. Kahl
Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.
Shira Zwebner
How to conquer the fear of your own body, one step at a time.
WE SURVIVORS ARE INUNDATED with the message: “Be hopeful!” Unfortunately, that universal rallying cry doesn’t help us know how to find hope or what to hope for.
Kristie L. Kahl
Long-term follow-up of the JULIET trial showed patients with relapsed or refractory DLBCL continued to experience durable responses 19 months after treatment.
Brielle Benyon
The Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) – the first biosimilar of Rituxan (rituximab) – to treat adults with CD20-positive, B-cell non-Hodgkin lymphoma (NHL).
Katie Kosko
Preventing febrile neutropenia is crucial because the body’s white blood cells help to fight infection.
Understanding the difference between cure and remission in non-Hodgkin lymphoma and overcoming anxiety and adjusting to life after treatment ends.
Loretta J. Nastoupil, MD, reinforces the role of multidisciplinary care throughout the cancer journey and explains why healthcare professionals such as herself recommend that patients keep an open dialogue with all members of their cancer care team.
Patient Whitney Neighbors discusses the benefits of connecting with MD Anderson’s Integrative Medicine Center and support groups or other integrative medicine clinics following a diagnosis of cancer.
Patient and physician considerations for switching between Rituxan IV and Rituxan Hycela, the subcutaneous formulation, during non-Hodgkin lymphoma treatment.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other